A research team led by the La Jolla Institute for Allergy & Immunology and Albany Medical College has illuminated the important role of natural killer (NK) T cells in Lyme disease, demonstrating that the once little understood white blood cells are central to clearing the bacterial infection and reducing the intensity and duration of arthritis associated with Lyme disease.

Microbiologists at the University of Calgary have demonstrated the first direct visualization of the dissemination of Borrelia burgdorferi, the bacterium that causes Lyme disease.

The bacteria that cause Lyme disease, the most common tick-borne illness in the United States, can linger in mouse tissues long after a full round of antibiotic treatment is completed, report researchers from the University of California, Davis.

Lyme disease is the blight of countryside users but it may be prevented with a single injection, according to research published in the Journal of Medical Microbiology.

A study led by a University of Pennsylvania biologist in the tick-infested woods of the Hudson Valley is challenging the widely held belief that mice are the main animal reservoir for Lyme disease in the U.S.

Lyme disease in the U.S. is caused by a form of bacteria, the spirochete Borrelia burgdorferi, infecting humans by tick bites.

Findings from the first placebo-controlled study of chronic cognitive impairment after treated Lyme disease (also known as chronic Lyme encephalopathy) demonstrate that patients report moderate cognitive impairment, physical dysfunction comparable to patients with congestive heart failure, and fatigue comparable to patients with multiple sclerosis.

A guideline developed by the American Academy of Neurology finds conventionally recommended courses of antibiotics are highly effective for treating nervous system Lyme disease. However, there is no compelling evidence that prolonged treatment with antibiotics has any benefit in treating symptoms that persist following standard therapy.

A First! Lyme Research Center Opens at Columbia Through Partnership with Lyme Disease Association and Time For Lyme

Scientists at the U.S. Department of Energy's Brookhaven National Laboratory and collaborators at Stony Brook University have received U.S. Patent Number 7,179,448 for developing chimeric, or "combination," proteins that may advance the development of vaccines and diagnostic tests for Lyme disease.